Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947725 | 0.76 | MEN1 (0.74) | MEN1KMT2AHTTNPSR1SMO | |
| SCHEMBL27812347 | 0.76 | MEN1 (0.60) | MEN1KMT2AHTTNPSR1SMO | |
| SCHEMBL10623392 | 0.75 | ALDH1A1 (0.59) | KMT2ANPSR1HPGDKDM4ETSHR | |
| SCHEMBL3646218 | 0.72 | MEN1 (0.75) | MEN1KMT2AHTTNPSR1SMO | |
| SCHEMBL29210388 | 0.71 | EPHX2 (0.49) | HTR2C | |
| SCHEMBL30983319 | 0.71 | EPHX2 (0.49) | HTR2C | |
| SCHEMBL27564193 | 0.71 | HTR2C (0.45) | HTR2CHRH4 | |
| SCHEMBL10833639 | 0.71 | ADRB1 (0.50) | MEN1KMT2AHTTHTR2CHPGD | |
| SCHEMBL20431317 | 0.71 | MEN1 (0.40) | MEN1KMT2AHTTNPSR1SMO | |
| SCHEMBL30887031 | 0.70 | EPHX2 (0.48) | HTR2CHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230293534-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | SECURA BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4185279-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Secura Bio, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230108157-A1 | FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE | INTELLIKINE LLC | 2023-04-06 | — | — | US | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11479601-B2 | Antibodies specific to Sonic Hedgehog and method of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-11312718-B2 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | INFINITY PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20120010229-A1 | THERAPEUTIC REGIMENS FOR HEDGEHOG-ASSOCIATED CANCERS | INFINITY PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012006589-A2 | METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING | INFINITY PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006584-A2 | THERAPEUTIC REGIMENS FOR HEDGEHOG-ASSOCIATED CANCERS | INFINITY PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010230-A1 | METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING | ROYALTY SECURITY, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110183948-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011088404-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | INFINITY PHARMACEUTICALS , INC (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2170866-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | MEN1 471/4885KMT2A 670/4885HTT 163/4885 |
| US-11312718-B2 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | PIK3CA, AKT3, PIK3CD | MEN1 911/4885KMT2A 4067/4885HTT 1155/4885 |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | MEN1 1386/4885KMT2A 3819/4885HTT 823/4885 |
| US-20110183948-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | SHH, GLI1, SMO | MEN1 1812/4885KMT2A 1607/4885HTT 1628/4885 |
| US-20120010230-A1 | METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING | SHH, GLI1, SMO | MEN1 1027/4885KMT2A 2876/4885HTT 1354/4885 |
| US-20230108157-A1 | FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE | PIK3CA, PIK3CD, PIK3CG | MEN1 1593/4885KMT2A 3564/4885HTT 945/4885 |
| US-20230293534-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PI4KB | MEN1 1835/4885KMT2A 1006/4885HTT 3891/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | MEN1 1386/4885KMT2A 3819/4885HTT 823/4885 |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | MEN1 3126/4885KMT2A 2333/4885HTT 865/4885 |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | MEN1 3126/4885KMT2A 2333/4885HTT 865/4885 |
| US-20120010229-A1 | THERAPEUTIC REGIMENS FOR HEDGEHOG-ASSOCIATED CANCERS | GLI1, SHH, SMO | MEN1 1576/4885KMT2A 780/4885HTT 2893/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | MEN1 1860/4885KMT2A 985/4885HTT 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.